Clinical trial NCT03212261: Promoting Resiliency Among Lymphoma Survivors: The 3RP-Lymphoma
Official title: Promoting Resiliency Among Lymphoma Survivors: The 3RP-Lymphoma
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Lymphoma
Keywords: Lymphoma
Lead sponsor: Massachusetts General Hospital
Sponsor class: OTHER
Collaborators: name: American Cancer Society, Inc.
First posted: 2017-07-11
Enrollment: 37
Sex: ALL
Minimum age (years): 18
Maximum age (years): 64
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SUPPORTIVE_CARE

Brief summary: The Relaxation Response Resiliency Program (3RP) was developed by researchers at the MGH Benson-Henry Institute for Mind Body Medicine; This program has recently been adapted to target the needs of individuals who have completed treatment for lymphoma (3RP-Lymphoma).

Detailed description: The Relaxation Response Resiliency Program, or 3RP, was developed by researchers at the MGH Benson-Henry Institute for Mind Body Medicine. The 3RP is a group program that-through a variety of mind-body approaches, such as imagery, relaxation, and yoga-seeks to buffer stress and promote psychological resiliency and physical well-being.

The 3RP has not yet been carried out with individuals who have recently completed treatment for lymphoma. As such, the investigators have adapted the standard 3RP program to target the specific needs of lymphoma patients who are transitioning off active treatment. The investigators are conducting this study to see if the adapted program, the 3RP-Lymphoma, is effective at reducing stress and stress-related symptoms for people who have completed treatment for lymphoma within the past two years. To develop the 3RP-Lymphoma, the investigators conducted interviews with patients who had recently completed treatment to learn about their experiences and their preferences for topics they would want to include in a program tailored to their specific needs. The current phase of the feasibility study will examine if the adapted program is feasible, acceptable, and helps promote stress management among lymphoma survivors who are in the early stages of completing cancer treatment.

Eligibility criteria: Inclusion Criteria:

* Aged 18-64
* Within 2 years post-treatment completion for lymphoma
* English speaking
* Able and willing to provide informed consent
* Cancer treatment or follow-up for lymphoma at the MGH Cancer Center

Exclusion Criteria:

* Unwilling or unable to participate in the study
* Unable to speak or read English
* Is medically, psychiatrically, or otherwise unable to participate (as determined by a physician or study PI)
* Unwilling or unable to participate in group 3RP sessions delivered via the Partners Telehealth videoconferencing software
* Participation in qualitative interview during Phase 1 (DF/HCC 16-396)

Primary outcomes:
measure: Program Feasibility: Number of Participants Who Completed at Least 75% of the Treatment Sessions
timeFrame: 1 month after completing the 3RP-Lymphoma program
measure: Number of Participants Who Found the 3RP Program Acceptable
timeFrame: 1 month after completing the 3RP-Lymphoma program
Secondary outcomes:
measure: Number of Participants Who Were Eligible to Provide and Provided Hair Cortisol Samples
timeFrame: 1 month after completing the 3RP-Lymphoma program
Other outcomes:
Locations:
city: Boston
country: United States
facility: Massachusetts General Hospital
state: Massachusetts
Study officials:
affiliation: Massachusetts General Hospital
name: Giselle K. Perez, PhD
role: PRINCIPAL_INVESTIGATOR
References: